Maropitant-d3

Maropitant-d3 is the deuterium labeled Maropitant. Maropitant is a selective and orally active neurokinin (NK1) receptor antagonist. Maropitant acts by blocking the binding of substance P within the emetic center and the chemoreceptor trigger zone (CRTZ) . Maropitant is highly effective in preventing vomiting[1][2].

Product Specifications

CAS Number

[2124295-52-7]

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Neurokinin Receptor

Related Pathways

GPCR/G Protein; Neuronal Signaling; Others

Field of Research

Neurological Disease; Endocrinology

Solubility

10 mM in DMSO

Smiles

CC(C)(C)C1=CC=C(OC([2H])([2H])[2H])C(CN[C@@H]2[C@H](C(C3=CC=CC=C3)C4=CC=CC=C4)N5CCC2CC5)=C1

Molecular Formula

C32H37D3N2O

Molecular Weight

471.69

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Hay Kraus BL. Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone. Vet Anaesth Analg. 2013 Jan;40 (1) :28-34.|[3]Lesman SP, Boucher JF, Grover GS, et al. The pharmacokinetics of maropitant citrate dosed orally to dogs at 2 mg/kg and 8 mg/kg once daily for 14 days consecutive days. J Vet Pharmacol Ther. 2012 Nov 20.|[4]Alvillar BM, Boscan P, Mama KR, et al. Effect of epidural and intravenous use of the neurokinin-1 (NK-1) receptor antagonist maropitant on the sevoflurane minimum alveolar concentration (MAC) in dogs. Vet Anaesth Analg. 2012 Mar;39 (2) :201-5.|[5]Ramsey DS, Kincaid K, Watkins JA et al. Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs. J Vet Pharmacol Ther. 2008 Dec;31 (6) :538-43. doi: 10.1111/j.1365-2885.2008.00992.x.|[6]Benchaoui HA, Cox SR, Schneider RP et al. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. J Vet Pharmacol Ther. 2007 Aug;30 (4) :336-44.|[7]Maropitant